Biographies

Timothy E. Weaver, MS, PhD

Co-Director, Division of Pulmonary Biology

Professor, UC Department of Pediatrics

Phone: 513-636-7223

Fax: 513-636-7868

Email: tim.weaver@cchmc.org

Show All

Specialties

Research

Lung development; chaperone biology and diseases of protein misfolding; pulmonary fibrosis; asthma; respiratory distress syndrome; acute and chronic lung disease

Visit the Weaver Lab Site.

Biography

Dr. Weaver has a long-standing interest in lung development and disease. His early work with Dr. Whitsett uncovered the function of surfactant proteins SP-B and SP-C, a discovery that has profoundly influenced the treatment of respiratory distress syndrome and survival of pre-term infants worldwide. His current research is focused to the molecular pathways (ER stress and autophagy) that link mutations in the SFTPC gene (encoding surfactant protein C) to development of interstitial lung disease (ILD) in both children and adults. His work has been continuously funded by the National Institutes of Health since 1986, including a MERIT (R37) award from the National Heart, Lung and Blood Institute (2001-2011).

Dr. Weaver has trained 14 graduate students in the past 15 years and is the past director of the Molecular and Developmental Biology Graduate Program. During the same period of time he has trained 11 postdoctoral fellows, eight of whom are current faculty members at institutions in the US, Germany, France, Japan and UK.

Education and Training

BS: Biology, Bob Jones University, Greenville, South Carolina, 1975.

MS: Embryology, Hahnemann Medical College, Philadelphia, Pennsylvania, 1979.

PhD:
Developmental Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, 1983.

Postdoc: Molecular Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, 1986.

Publications

View PubMed Publications

Grants

Role of Autophagy in Pathogenesis of Interstitial Lung Disease. Principal Investigator. National Institutes of Health. Jul 2011 - Jun 2015. R01-HL103923.

Stard7, A Novel Inhibitor Of Allergic Lung Disease. Principal Investigator. National Institutes of Health. Dec 2013 - Nov 2017. R01-HL122130.